How Basket Trials Are Reshaping Drug Development Timelines for Rare Pediatric Diseases
核心洞察
Basket trials improve recruitment efficiency for rare pediatric diseases by allowing multiple indications to be studied at the same treatment centers under a single trial protocol.
The Bayesian statistical approach enables data sharing across indications within a basket trial, providing more robust efficacy assessments across different patient populations.
FDA and EMA have demonstrated commitment to rare disease drug development through dedicated review divisions, the Rare Disease Hub, and new guidance documents for industry.
Basket trials are emerging as a powerful tool to accelerate drug development for rare pediatric diseases, offering operational efficiencies and enhanced data utilization that traditional trial designs cannot match. In a recent interview with Pharmaceutical Executive, Lisa Bollinger, chief medical officer at Polaryx (搜索), detailed how this trial design is transforming the landscape for the clinical-stage biotech, which focuses on treatments for rare pediatric lysosomal storage disorders (搜索).
Bollinger explained that while basket trials have existed for some time—particularly in oncology—their impact on large-population oncology indications has been limited. The real value, she noted, emerges in rare disease settings, especially in pediatrics. "When you look at rare oncology indications (especially in pediatrics), that's where basket trials started being used to help support rare disease development," Bollinger said.
Operational and Recruitment Advantages
One of the most significant benefits of the basket trial design is its ability to streamline patient recruitment. Because rare diseases are frequently treated at the same specialized centers, a single basket trial can recruit across multiple disease arms simultaneously. "If you have a study that's set up at a center that serves a lot of the CLNs, they're able to recruit for all of the different arms of the basket study at the same time," Bollinger explained. "You can imagine this is a lot more efficient than standing up individual trials for each of these rare diseases and trying to find out what hospitals treat these specific rare diseases."
Polaryx (搜索)'s Soteria trial exemplifies this approach, incorporating four arms across four different indications within a single trial structure. Bollinger emphasized the operational efficiency: "It allows us to stand up a single trial at these centers, so it's much easier from an operational standpoint to set up one single trial than it is to set up four individual trials at the same sites."
Leveraging Data Through Bayesian Methods
Beyond recruitment, basket trials enable a more sophisticated approach to data analysis. The Bayesian statistical method allows researchers to incorporate existing, relevant data alongside new clinical trial findings—an approach that the FDA has actively supported through regulatory updates expanding the range of permissible data in clinical trials.
"If you have diseases with commonality and you have them all in the same basket trial and you're getting results at the same time, there is this ability to use a Bayesian approach, which really borrows known prior information across indications," Bollinger said. "This makes it easier to recruit, and it also makes it easier to share data across indications to then provide a more robust assessment of efficacy across different populations."
This data-sharing capability is particularly critical in rare disease spaces where limited patient populations constrain traditional statistical approaches.
A Supportive Regulatory Environment
The adoption of innovative trial designs like basket trials is occurring alongside a strengthening regulatory infrastructure for rare pediatric diseases. Bollinger described the current regulatory landscape at both the FDA and European Medicines Agency as "very robust," pointing to concrete organizational changes that signal genuine commitment.
"What we've really seen over the last couple of years is a commitment to developing therapies for rare diseases, and this is really evidenced by the formation of a rare disease review division within the centers at CBER, as well as some additional offices like the Rare Disease Hub and Rare Disease representation within the Office of the Commissioner," Bollinger noted.
She added that when agencies invest in staffing and collaborative infrastructure across different centers, it demonstrates that "the regulators are really rallying around rare disease." Both the FDA and EMA have also advanced several guidances for industry to assist rare disease companies in navigating trial development and drug study processes.
The convergence of flexible trial designs, Bayesian statistical frameworks, and a supportive regulatory environment is creating new possibilities for companies like Polaryx (搜索) to advance therapies for underserved rare pediatric disease populations.